Novartis AG is 75.4x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($282.64 B vs $3.75 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KNSA | NVS |
|---|---|---|
| Market cap | $3.75 B | $282.64 B |
| US-listed rank | #1625 | #47 |
| Revenue (latest FY) | $677.56M | - |
| Net income (latest FY) | $59.01M | - |
| Net margin | 8.7% | - |
| P/E (trailing FY) | 63.6 | - |
| SEC filings | 733 | 947 |
Novartis AG is 75.4x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($282.64 B vs $3.75 B).
Full pages: Kiniksa Pharmaceuticals, Ltd. and Novartis AG, or browse the full rankings.